PRQR

Proqr Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth 0/10
  • Value 0/10
Proqr Therapeutics sales and earnings growth
PRQR Growth
Low
  • Revenue Y/Y -30.60%
  • EPS Y/Y -34.38%
  • FCF Y/Y -25.07%
Proqr Therapeutics gross and profit margin trends
PRQR Profitability
Low
  • Gross margin 100.00%
  • EPS margin -333.50%
  • ROIC 5Y -1134.66%
Proqr Therapeutics net debt vs free cash flow
PRQR Risk
Great
  • Debt / Equity 0.4
  • Debt / FCF 0.0
  • Interest coverage -28.7

Proqr Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks